期刊文献+

头孢西酮钠对临床分离细菌感染小鼠的保护作用 被引量:2

The effect of cefazedone sodium on mice infected by clinically isolated bacteria
下载PDF
导出
摘要 目的探讨头孢西酮钠对临床分离菌株感染小鼠的保护作用。方法给小鼠腹腔注射临床分离的金黄色葡萄球菌、铜绿假单胞菌和大肠埃希菌,感染后皮下注射头孢西酮钠,观察记录感染后小鼠的生存率。结果头孢西酮钠10mg/kg、20mg/kg和40mg/kg能显著降低中间葡萄球菌R1725株、金黄色葡萄球菌R1743株、铜绿假单胞菌R1620株、铜绿假单胞菌R1598株、大肠埃希菌R1598株、大肠埃希菌W1867株和D群肠球菌W1999株感染小鼠的死亡率。结论头孢西酮钠对临床分离的金黄色葡萄球菌、铜绿假单胞菌和大肠埃希菌感染小鼠有显著的保护作用。 Objective To study the effect of cefazedone sodium on mice infected by clinically isolated bacteria. Methods The mice were injected clinically isolated strains of staphylococcus aureus, pseudomonas aeruginosa( P. aeruginosa)and escherichia coli by intraperitoneal route. Then the infected mice were injected cefazedone sodium by subcutaneous route. Results Cefazedone sodium of 10 mg/kg,20 mg/kg and 40 mg/kg decreased the mortality rate of mice infected by staphylococcus intermediu R1725, staphylococcus aureus 1743, pseudomonas aeruginosa R1620, pseudomonas aeruginosa R1598, escherichia coli R1598, escherichia coli W1867 and enterococci W1999. Conclusion Cefazedone sodium can protect mice infected by clinically isolated staphylococcus aureus,pseudomonas aeruginosa,and escherichia coli.
出处 《中国实用医药》 2008年第1期17-19,共3页 China Practical Medicine
关键词 头孢西酮钠 葡萄球菌 铜绿假单胞菌 大肠埃希菌 Cefazedone sodium Staphylococcus aureus Pseudomonas aeruginosa ( P. aeruginosa ) Escherichia coli
  • 相关文献

参考文献10

二级参考文献26

  • 1王飞燕,张伟,杨方伦.心血管病患者血培养的病原菌分类及耐药性分析[J].中国热带医学,2005,5(1):136-137. 被引量:2
  • 2陈林,王其南,蒋玉富,郑行萍,刘鸿渝,李崇智.TEICOPLANIN体外抗菌活性研究[J].重庆医科大学学报,1994,19(3):173-176. 被引量:2
  • 3戴自英.实用抗菌药物学[M].上海:上海科学技术出版社,1994.189.
  • 4徐淑云 卞如濂 等.药理学实验方法(第2版)[M].北京:人民卫生出版社,1994.1340.
  • 5杨明华.头孢克洛[J].国外医药·抗生素分同,1988,9(1):31-33.
  • 6Pena A,Derendorf H. Pharmaeokinetic properties of beta-lactamase inhibitors[J ]. Int J Clin Pharmacol Ther ,1999,37(2) :63 - 75.
  • 7Kim MK,Capitano B, Mattoes HM, et al. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam [ J ]. Pharmacotherapy, 2002, 22 ( 5 ):569- 577.
  • 8Burgess DS,Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing[J]. Clin Ther ,2002,24(7) : 1090 -1104.
  • 9Rodriguez JA, Trujillano I. Second Multicenter study of the in vitro susceptibility to piperacillin-tazobactam [ J ]. Rev Esp Quimioter ,2002,15(2) : 169 - 75.
  • 10Verbist L, Verhaegen J,Wouters C, et al. Comparative activity of piperacillin/tazobactam against 5625 isolates from hospitalised patients. Multicentre Study Group [J ]. J Antimicrob Chemother,1996,37(2) : 285 - 293.

共引文献33

同被引文献4

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部